Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

被引:12
作者
Liu, Pan [1 ]
Jin, Yanxia [1 ]
Sattar, Haseeb [2 ]
Liu, Hailing [3 ]
Xie, Weiling [1 ]
Zhou, Fuling [1 ,4 ]
机构
[1] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Hosp, Dept Clin Pharm,Wuhan Union Hosp, Wuhan, Hubei, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Clin Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China
[4] Hubei Key Lab Tumor Biol Behav, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
immunotherapy; multiple myeloma; natural killer cell; HLA CLASS-I; NK CELLS; MEDIATED LYSIS; MONOCLONAL-ANTIBODIES; CANCER-IMMUNOTHERAPY; BISPECIFIC ANTIBODY; THERAPEUTIC TARGET; ADOPTIVE TRANSFER; T-CELLS; ACTIVATION;
D O I
10.1002/JLB.2RU0517-176RR
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Multiple myeloma (MM) is a complex aggressive mature B-cell malignancy. Although with the wide application of chemotherapy drugs, it remains incurable and the vast majority of patients relapse. Natural killer (NK) cells, also known as CD56(+)CD3(-) large granular lymphocytes, are cytotoxic innate immune cells against MM without prior sensitization steps. NK cell-based immunotherapy is extensively promising in a wide range of clinical settings. It is worthy of note that some novel drugs such as monoclonal antibodies (mAbs), proteasome inhibitors (PIs), and immunomodulators (IMiDs) directly or indirectly activate NK cells to enhance their antitumor activity, and the combined regimens significantly improve the prognosis of MM patients. In this review, we summarize recent findings that support a role for NK cells in the pathogenesis of MM and outline innovative approaches in the implementation of NK cell-based immunotherapy against MM. Review on NK cell dysfunction in patients with multiple myeloma.
引用
收藏
页码:821 / 828
页数:8
相关论文
共 95 条
[1]  
[Anonymous], 2015, BIOMED RES INT
[2]   Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors [J].
Aporta, Adriana ;
Catalan, Elena ;
Galan-Malo, Patricia ;
Ramirez-Labrada, Ariel ;
Perez, Marta ;
Azaceta, Gemma ;
Palomera, Luis ;
Naval, Javier ;
Marzo, Isabel ;
Pardo, Julian ;
Anel, Alberto .
BIOCHEMICAL PHARMACOLOGY, 2014, 87 (03) :410-423
[3]   Chimeric Antigen Receptor (CAR) therapy for multiple myeloma [J].
Atanackovic, Djordje ;
Radhakrishnan, Sabarinath V. ;
Bhardwaj, Neelam ;
Luetkens, Tim .
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) :685-698
[4]   Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. Autologous Transplantation-Novel Agents and Immunomodulatory Strategies [J].
Avigan, David ;
Hari, Parameswaran ;
Battiwalla, Minoo ;
Bishop, Michael R. ;
Giralt, Sergio A. ;
Hardy, Nancy M. ;
Kroeger, Nicolaus ;
Wayne, Alan S. ;
Hsu, Katharine C. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (12) :1661-1669
[5]   Immunotherapy for multiple myeloma: Current status and future directions [J].
Ayed, Ayed O. ;
Chang, Lung-Ji ;
Moreb, Jan S. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (03) :399-412
[6]   Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways [J].
Balasa, Balaji ;
Yun, Rui ;
Belmar, Nicole A. ;
Fox, Melvin ;
Chao, Debra T. ;
Robbins, Michael D. ;
Starling, Gary C. ;
Rice, Audie G. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (01) :61-73
[7]   A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].
Benson, Don M., Jr. ;
Hofmeister, Craig C. ;
Padmanabhan, Swaminathan ;
Suvannasankha, Attaya ;
Jagannath, Sundar ;
Abonour, Rafat ;
Bakan, Courtney ;
Andre, Pascale ;
Efebera, Yvonne ;
Tiollier, Jerome ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2012, 120 (22) :4324-4333
[8]   The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Mishra, Anjali ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Becknell, Brian ;
Baiocchi, Robert A. ;
Zhang, Jianying ;
Yu, Jianhua ;
Smith, Megan K. ;
Greenfield, Carli N. ;
Porcu, Pierluigi ;
Devine, Steven M. ;
Rotem-Yehudar, Rinat ;
Lozanski, Gerard ;
Byrd, John C. ;
Caligiuri, Michael A. .
BLOOD, 2010, 116 (13) :2286-2294
[9]  
Bigley AB, 2015, DISCOV MED, V19, P433
[10]   Recent major improvement in long-term survival of younger patients with multiple myeloma [J].
Brenner, Hermann ;
Gondos, Adam ;
Pulte, Dianne .
BLOOD, 2008, 111 (05) :2521-2526